APA (7th ed.) Citation

Macdonald, R. L., Higashida, R. T., Keller, E., Mayer, S. A., Molyneux, A., Raabe, A., . . . Kassell, N. (2011). Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet neurology, 10(7), 618-625. https://doi.org/10.1016/S1474-4422(11)70108-9

Chicago Style (17th ed.) Citation

Macdonald, R Loch, et al. "Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Haemorrhage Undergoing Surgical Clipping: A Randomised, Double-blind, Placebo-controlled Phase 3 Trial (CONSCIOUS-2)." Lancet Neurology 10, no. 7 (2011): 618-625. https://doi.org/10.1016/S1474-4422(11)70108-9.

MLA (9th ed.) Citation

Macdonald, R Loch, et al. "Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Haemorrhage Undergoing Surgical Clipping: A Randomised, Double-blind, Placebo-controlled Phase 3 Trial (CONSCIOUS-2)." Lancet Neurology, vol. 10, no. 7, 2011, pp. 618-625, https://doi.org/10.1016/S1474-4422(11)70108-9.